{"brief_title": "A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia", "brief_summary": "A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia", "detailed_description": "Study will evaluate long-term safety and tolerability of a new compound in the treatment of patients with schizophrenia as assessed by adverse events (AEs), measures of extra pyramidal symptoms (EPS; Abnormal Involuntary Movement Scale [AIMS], Barnes Akathisia Scale [BAS], and Simpson-Angus Rating Scale [SAS]), vital sign measurements, electrocardiograms (ECGs), clinical laboratory evaluations.", "condition": ["Schizophrenia"], "intervention_type": ["Drug"], "intervention_name": ["Lurasidone 80mg tablet"], "arm_group_label": ["Lurasidone 80 mg tablet"], "other_name": ["Lurasidone"], "criteria": "- Patients must have participated in study D1050196 (A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia) and either: - Successfully completed - OR - Patients must have been discontinued after a minimum of 2 weeks of treatment due to lack of efficacy", "gender": "All", "minimum_age": "18 Years", "maximum_age": "64 Years", "healthy_volunteers": "No", "keyword": "Lurasidone", "mesh_term": ["Schizophrenia", "Lurasidone Hydrochloride"], "id": "NCT00088621"}